Search
Call Details
- Programme: EU4Health 2021–2027
- Call Number: EU4H-2026-SANTE-PJ-08
- Opening Date: 23 September 2025
- Deadline: 6 January 2026, 17:00 CET
- Funding Rate: 60%
- Total Call Budget: €14,386,810
- Estimated EU Contribution Per Project: Up to the full call budget
- Submission Link & Call Documents: via the EU funding & tenders portal
Call Description
Brief Description
The general aim of this action is to accelerate the development and deployment of AI and digital solutions in the biotech sector based on health data, ensure their safe and responsible use under the European Health Data Space (EHDS), and deploy AI factories to reinforce these efforts.
Objectives of the Call
- Establish a multi-stakeholder platform / community of practice bringing together biotech industry, research institutions, health care providers, patient organisations, regulators and AI factories, to facilitate collaboration, knowledge exchange, and discussion of AI challenges in biotech.
- Conduct a landscape analysis: map the current use of health data for AI in biotech and identify key health datasets relevant for biotech use, based on impact, feasibility and alignment with sector needs. Potential involvement of AI factories in this analysis is encouraged.
- Develop a strategic roadmap: propose plans for development, deployment, and scaling of effective AI solutions in biotech, including policy recommendations. Promote standardised data formats and frameworks relevant to biotech, leveraging AI factory capabilities and existing infrastructures.
- Pilot roles for health data infrastructures within the EHDS: analyse and test how specific health data infrastructures (e.g. genomics, cancer imaging, brain) can be integrated in the EHDS, including access to computing resources and support services, to drive AI-driven biotech innovations.
- Develop case studies of AI applications in biotech, focusing on explainability, to highlight good practices and lessons learned.
- Integrate expertise from AI factories: combine technological advances of AI factories with EHDS infrastructure use for simulations and analyses to refine AI solutions tailored to health sector needs.
- Monitor and evaluate progress: test methodologies and tools to track advancement relative to the strategic roadmap, enabling learning and adaptation for continuous improvement.
Expected Effects & Impacts
- Strengthened collaboration and knowledge exchange among stakeholders in biotech and health sectors
- Accelerated innovation in the EU’s biotech industry through AI / digital solutions
- Improved health outcomes via broader adoption of AI in biotech
- Greater legal clarity through articulation of regulatory frameworks and standards for AI in biotech and integration of health data infrastructures in EHDS
Eligibility Criteria
Eligible Countries / Regions
- EU Member States and Overseas Countries and Territories
- Bosnia and Herzegovina, Iceland, Moldova, Montenegro, Norway, Ukraine
Eligible Organisations
- Education and training institutions
- Research organisations, including universities
- International organisations
- SMEs
- Non-profit / non-governmental organisations
- Private (for-profit) organisations
- Public bodies (national, regional, local), including European Groupings of Territorial Cooperation (EGTC)
Partnership Requirements
- Mandatory consortium: proposals must be submitted by a consortium with at least 5 beneficiaries from 5 different eligible countries
- Applicants must be legal entities (public or private) based in eligible countries
- Natural persons are not eligible (except for self-employed persons in cases where their enterprise is not legally distinct)
- International organisations are eligible (without country restrictions)
- Entities without legal personality may exceptionally participate if they can assume legal obligations and financial guarantees equivalent to legal persons
- EU institutions (except the Joint Research Centre) are not eligible to participate as beneficiaries
- Associations and interest groups may participate as single beneficiaries or beneficiaries without legal personality; however, if they execute actions via their members, those members must also be part of the project (either as beneficiaries or linked entities) for their costs to be eligible
- European Reference Networks (ERNs) may participate, especially in rare diseases, consistent with Directive 2011/24/EU
- Entities from countries currently negotiating association status may be eligible if negotiations are concluded before grant signature and retroactive coverage is allowed
- Special rules apply for entities under EU restrictive measures or conditionality rules — such institutions are ineligible for funding
Additional Information
- Topics: Digitalisation / Digital Society / ICT, Health / Social / Sport
- Project duration: 24 to 36 months
- Proposals must be submitted electronically via the online submission system; no paper submissions accepted
- Proposals must be complete, containing all required information, attachments, and supporting documentation (admin, technical forms, budget tables, CVs, previous project lists)
- Part B (technical description) is limited to maximum 70 pages
- Third-party financial support is allowed under conditions of open, transparent procurement meeting EU standards
- Further call documents and templates are provided on the portal
Contact
- European Health and Digital Executive Agency (HaDEA) – National Contact Points
- Email: HaDEA-HP-CALLS@ec.europa.eu